Research identifies RNA structures linked to Parkinson’s
HQ Team November 20, 2024: A team of researchers from Kumamoto University has found that unique RNA structures known as G-quadruplexes (G4s) facilitate.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team November 20, 2024: A team of researchers from Kumamoto University has found that unique RNA structures known as G-quadruplexes (G4s) facilitate.
HQ team November 20, 2024: Your inclination to get up from the couch to go for a run or remain slouched there is.
More than 30 nations, which combined account for 47% of global methane emissions from organic waste, signed a pact to reduce levels by.
A sedentary lifestyle of more than 10.6 hours a day increases heart disease by up to 60%, according to a study by Mass.
HQ Team November 19, 2024: The European Medicines Agency (EMA) granted conditional approval for lecanemab, for the treatment of early Alzheimer’s disease in.
HQ Team November 19, 2024: The emergence of AI technology as a diagnostic tool is slowly changing how health professionals view patient care..
HQ Team November 16, 2024: Shingles vaccination has proven effective in preventing herpes zoster and its related complications. Recent research suggests that the.
Measles cases worldwide have risen 20% year-on-year in 2023 to about 10.3 million due to inadequate access to vaccines, according to new estimates.
HQ Team November 15, 2024:Allergies are a source of great social and physical impairment for people suffering from them. Treatments are long-drawn, expensive.
HQ Team November 15, 2024: Eli Lilly’s Phase III trial has yielded positive results from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for.